Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Pfizer - The Real Truth

Ahead of Market: 10 things that will decide stock market action on Wednesday

Indian equities extended their decline on Tuesday, with Sensex falling 555 points and Nifty ending below 23,650. Analysts cited elevated crude prices, Fed rate hike concerns and IPO fund absorption, while technical signals suggested 23,600 as key Nifty support.

The Economic Times

360 One Group CEO Bhagat buys 1.3 lakh shares of Novartis India for Rs 22 cr

Karan Bhagat acquired 1.3 lakh Novartis India shares for nearly Rs 22 crore. His firm Kyrush Investments sold an equal number of shares in the transaction. Novartis India also announced acquiring trademarks from Pfizer for Rs 1,250 crore. Earlier, Novartis AG agreed to sell its stake to a consortium. This…

The Economic Times

Men Genetically Prone to Baldness Carry a 7 Percent Added Hair Loss Risk Tied to GLP-1 Biology

An NYU Langone genetic study links GLP-1 receptor activity to a 7 percent increased risk of male pattern hair loss. What the finding does and does not show.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Stocks for Investors Who Still Believe Cash Is King

As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.

MarketBeat

Teens and Young Adults Who Caught COVID Without Vaccination Had the Highest Recorded Heart Inflammation and Death Rates

A study of nearly 4.1 million people aged 16 to 25 compared heart inflammation and death rates after COVID infection and after Pfizer-BioNTech vaccination.

Medical Daily

Updated COVID Shots Matched to the XFG Variant Reach Pharmacies While Federal Eligibility Guidance Remains Unsettled

FDA approved updated 2026-2027 COVID vaccines targeting XFG. Here is who qualifies, what insurance covers, and what guidance is still missing.

Medical Daily

FDA approves updated Covid-19 vaccines for dominant XFG variant

Decision allows manufacturers to begin shipping doses, but confusion remains about insurance coverage

The Guardian - US

Read news from The Economist, FT, and more,
with one subscription

Heart Inflammation Was More Common After COVID Infection Than After Pfizer Vaccination in Four Million Young People

A study of 4.1 million people ages 16 to 25 compared myocarditis after COVID infection with myocarditis after vaccination. Here is what it found.

Medical Daily

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart

CFO turnover at America's largest companies is on pace to hit 18.3%—the highest since the pandemic

The next generation of CFOs stepping in may be younger and less experienced.

Fortune

Australian Data Put the Maternal RSV Vaccine at 78 Percent Effective Against Infant Lung Infection Admissions

A JAMA Pediatrics study of 1,012 hospitalized infants found maternal RSV vaccine effectiveness to be 77.8% against lung infection admissions through six months.

Medical Daily

COVID Vaccination Averted an Estimated 4,307 Deaths in King County During the First Eight Months of Rollout

A King County modeling study estimates COVID vaccination averted 16,607 hospitalizations and 4,307 deaths during the first eight months of rollout.

Medical Daily

Expectant Parents Have Two Ways to Shield a Newborn from RSV Before the Season Opens in the Fall

Two RSV options can protect a newborn this season. Here is the timing, the hospitalization data, and what to ask a pediatrician now.

Medical Daily

First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often…

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

The Economic Times

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

Medical Daily

Pfizer's Vitiligo Pill Shows Promise as Doctors Explain Why the Condition Is More Than Skin Deep

Pfizer says Phase 3 trials show Litfulo helped restore skin pigmentation in nonsegmental vitiligo, marking a promising advance in treatment.

Benzinga

SpaceX Could Swing $204 Billion After Earnings

Earnings are set to hit the tape in a tight window on Tuesday, and the options market is already sketching out how much volatility traders expect once results and guidance land, according to Benzinga Pro.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Pregnant Patients Caught Between Two Vaccine Schedules Now Have Infant Hospitalization Numbers to Bring to the Appointment

ACOG and CDC guidance on pregnancy vaccines now differ. New research shows maternal RSV vaccination cut infant hospitalizations by about 68 percent.

Medical Daily

FDA Sets a Late-2026 Decision on Adding a PARP Inhibitor to Hormone Therapy for Advanced Prostate Cancer

FDA granted priority review to talazoparib plus enzalutamide for HRR-altered metastatic prostate cancer. A decision is expected in late 2026.

Barchart

Is Wall Street Bullish or Bearish on Pfizer Stock?

While Pfizer has trailed the broader market over the past year, Wall Street still sees room for upside and remains moderately optimistic about the company's prospects.

Benzinga

GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out'

Rep. Thomas Massie (R-Ky.) questioned Vice President JD Vance‘s silence after the Trump administration established billions for Pfizer Inc.‘s (NYSE:PFE) COVID-19 vaccine contracts for 2026 and 2027.

Medical Daily

Only Available Syphilis Shot for Pregnancy Remains in Short Supply Through Early Next Year

Bicillin L-A, the only treatment for syphilis in pregnancy, is short until late 2027. What pregnant patients and clinicians should do now.

International Business Times

Pfizer and the $200 Billion-Dollar Cardiovascular Market

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the rapidly growing $200 billion heart disease market.

The Conversation

When can a power company take your land for data center infrastructure?

The artificial intelligence boom in the United States is being matched by a data center building boom. There are more than 3,000 data centers in the U.S. and another 1,500 in development, according to a Pew Research Center analysis.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.